SCI — Annual Report 2013

May 6, 2013

員工數Employee:190 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣493佰萬元(NTD 493mn) 營業項目Business: 原料藥API(42.80%) 中間體Intermediate(43.68%) 特用化學品 Custom-made chemicals(13.52%)

公司概況 Outline

	Y2012	2013
		Jan.- Apr.
歐洲Europe	41.74%	34.36%
美洲America	22.11%	24.39%
亞洲Asia	18.15%	26.46%
國內Taiwan	18.00%	14.79%
計Total 合	100.00%	100.00%

Unit: K NTD

	2012	2013
		Jan.-Apr.
營收Sales	1,262,572	432,919
營業成本COGS	(864,684)	(298,920)
毛利Gross Profit	397,888	133,999
毛利率 GP Ratio	31.5%	31.0%
營業費用Operating Expenses	(146,039)	(49,809)
營業利益Operating Income	251,849	84,190
營業外損益Non-Operating In/Ex	(13,695)	(3,443)
稅前淨利 Net Profit before Tax	238,154	80,747
所得稅Income Tax	(43,705)
稅後淨利Net Profit after Tax	194,449

產品組合-Products

Y2011	%		Y2012	%	Y2013	%	Amount
Di-VaNa	24.51%	V.A.		18.66%	V.A.	16.15%	69,895,168
PGA	17.65%		PGA	16.61%	Di-VaNa	14.77%	63,962,953
V.A.	13.76%		Di-VaNa	15.97%	PGA	13.21%	57,174,869
PPON	10.70%		PPON	7.88%	PPON	5.67%	24,526,297
M85	5.25%		Pent-2	4.78%	LPF.Na	4.93%	21,328,269
Pent-2	3.73%		5-HMT	4.33%	P20	4.74%	20,507,658
DBS	3.08%	M85		3.89%	Pent-2	4.01%	17,344,469
M115	2.55%		DBS	2.73%	DBS	3.67%	15,886,688
M74	2.31%		M115	2.59%	5-HMT	3.46%	14,997,760
NBE	1.87%	M74		2.18%	MQR-85L	3.27%	14,154,000
Total	85.40%		Total	79.62%	Total	73.87%

DEDPM VA

NaVa

Valproic Acid (VA)

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customers

Propiophenone (PPON)- Bupropion 產品介紹Product 107,755 176,657 146,583 178,493 123,507 111,020 99,450 - 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 2006 2007 2008 2009 2010 2011 2012 Sales Sales

第一項產品 First product

15個客戶 15 customers

52,253 47,758 37,509 38,665 60,410 - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2006 2007 2008 2009 2010 2011 2012 Sales Sales

Pent-2

Pentobarbital Sodium

鎮定安眠用之原料藥 API used as calmative

• 2011年開始銷售6佰萬 6mn, starting in 2011. 2012銷售額23佰萬 23mn sales in 2012

第二項產品 Second product 5個客戶 5 customers

4個客戶 4 customers

Hydroxychloroquine

• 2011年開始銷售10.8佰萬 10.8 mn, starting in 2011
• 2012年銷售額33.6佰萬 33.6mn sales in 2012
• 治療風濕性關節炎原料藥(Hydroxychloroquine sulfate) API : Hydroxychloroquine sulfate for rheumarthritis
• 原料藥市場約20噸100 佰萬 API market: 20 MT, 100mn

Anti-inflammatory (Loxoprofen sodium) 2012年銷售5個客戶5佰萬 5 customers, 5 mn sales in 2012. 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg

5-HMT – Ritonavir,Lopinavir

5-Wing– Ritonavir,Lopinavir 2012年開始銷售5.7佰萬 5.7mn, starting in 2012 愛滋病藥物之中間體 For AIDS treatment

產品介紹Product

Antidepressant ( Duloxetine ) 2013年底專利到期 Patent will expire in the end of 2013 2011銷售9.5佰萬予10個客戶 9.5 mn sales consisting of 10 customers in 2011 2012年銷售額8佰萬 8 mn sales in 2012 2011及2012年中間體S-MMAA分別銷售2佰萬及1佰萬 S-MMAA(Intermediate) : 2 mn in 2011, 1mn in 2012. 2010年美國市場製劑銷售值美金31億 USD 3.1 billion in formulation in America in 2010

4-CPE

Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API

GMP Status(GMP現況)

API	CGMP certified	CEP	DMF	MF	DMF
	(TFDA)	(EDQM)	(USA)	(Japan)	(Canada)
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011
Probucol	2004		2004
Sodium Valproate	2004	2006
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006
Pentobarbital Sodium	2009	2011
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011
Duloxetine Hydrochloride	2012		2010/2011
Thiopental acid	2012
Loxoprofen Sodium Hydrate	2012			2011
Articaine Hydrochloride	2013
Clindamycin Palmitate HCl			2011
Cyclophosphamide			2012

敬 請 指 教